On the mechanisms for the selective action of vitamin D analogs

A variety of analogs of 1,25-(OH)2D3 with less calcemic activity and lower receptor binding affinity than 1,25-(OH)2D3 have been developed. However, these compounds have equal or greater ability to differentiate leukemia cells and psoriatic fibroblasts and to suppress PTH synthesis and secretion. Th...

Full description

Saved in:
Bibliographic Details
Published inEndocrinology (Philadelphia) Vol. 128; no. 4; p. 1687
Main Authors Dusso, A S, Negrea, L, Gunawardhana, S, Lopez-Hilker, S, Finch, J, Mori, T, Nishii, Y, Slatopolsky, E, Brown, A J
Format Journal Article
LanguageEnglish
Published United States 01.04.1991
Subjects
Online AccessGet more information

Cover

Loading…
Abstract A variety of analogs of 1,25-(OH)2D3 with less calcemic activity and lower receptor binding affinity than 1,25-(OH)2D3 have been developed. However, these compounds have equal or greater ability to differentiate leukemia cells and psoriatic fibroblasts and to suppress PTH synthesis and secretion. The mechanism for this selectivity has not been elucidated. Because the lower potency of ergocalciferol compared to cholecalciferol in preventing or curing rickets in chicks was associated with a lower affinity of the avian vitamin D binding protein (DBP) for vitamin D2, we tested five analogs with low calcemic activity including 22-oxa-1,25-(OH)2D3 (OCT), MC903, 1,25-(OH)2-16 ene-23-yne D3, 1,25-(OH)2-26,27 dihomo-22-ene-D3, and 1,25-(OH)2-24-trihomo-22-ene-D3 for their affinity for rat serum DBP. All analogs had a low affinity for DBP, ranging from 50-3000 times less than that of 1,25-(OH)2D3. OCT also bound with low affinity to dog and human serum DBP. We tested with OCT the possible consequences of its low affinity for serum DBP. One of the functions of DBP is to prolong the lifetime of 1,25-(OH)2D3 in circulation. Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6-7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min). The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3. As our primary interest is the potential of OCT in treating the secondary hyperparathyroidism of CRF, we also measured the MCR of OCT in 5/6 nephrectomized dogs. Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4). Despite its shorter half-life, OCT suppressed PTH secretion in vivo in uremic dogs. The effects of low binding to DBP on the percentage uremic dogs. The effects of low binding to DBP on the percentage of free sterol were determined using an ultrafiltration procedure. We compared the proportion of free (unbound) OCT and 1,25-(OH)2D3 in 0.1% BSA-PBS with concentrations of human serum ranging from 0-25%. The proportion of OCT in the free form was significantly higher than that of 1,25-(OH)2D3 for every serum concentration tested. The physiological relevance of a higher percentage of free OCT was tested in normal human macrophages.
AbstractList A variety of analogs of 1,25-(OH)2D3 with less calcemic activity and lower receptor binding affinity than 1,25-(OH)2D3 have been developed. However, these compounds have equal or greater ability to differentiate leukemia cells and psoriatic fibroblasts and to suppress PTH synthesis and secretion. The mechanism for this selectivity has not been elucidated. Because the lower potency of ergocalciferol compared to cholecalciferol in preventing or curing rickets in chicks was associated with a lower affinity of the avian vitamin D binding protein (DBP) for vitamin D2, we tested five analogs with low calcemic activity including 22-oxa-1,25-(OH)2D3 (OCT), MC903, 1,25-(OH)2-16 ene-23-yne D3, 1,25-(OH)2-26,27 dihomo-22-ene-D3, and 1,25-(OH)2-24-trihomo-22-ene-D3 for their affinity for rat serum DBP. All analogs had a low affinity for DBP, ranging from 50-3000 times less than that of 1,25-(OH)2D3. OCT also bound with low affinity to dog and human serum DBP. We tested with OCT the possible consequences of its low affinity for serum DBP. One of the functions of DBP is to prolong the lifetime of 1,25-(OH)2D3 in circulation. Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6-7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min). The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3. As our primary interest is the potential of OCT in treating the secondary hyperparathyroidism of CRF, we also measured the MCR of OCT in 5/6 nephrectomized dogs. Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4). Despite its shorter half-life, OCT suppressed PTH secretion in vivo in uremic dogs. The effects of low binding to DBP on the percentage uremic dogs. The effects of low binding to DBP on the percentage of free sterol were determined using an ultrafiltration procedure. We compared the proportion of free (unbound) OCT and 1,25-(OH)2D3 in 0.1% BSA-PBS with concentrations of human serum ranging from 0-25%. The proportion of OCT in the free form was significantly higher than that of 1,25-(OH)2D3 for every serum concentration tested. The physiological relevance of a higher percentage of free OCT was tested in normal human macrophages.
Author Dusso, A S
Brown, A J
Lopez-Hilker, S
Nishii, Y
Mori, T
Gunawardhana, S
Negrea, L
Finch, J
Slatopolsky, E
Author_xml – sequence: 1
  givenname: A S
  surname: Dusso
  fullname: Dusso, A S
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110
– sequence: 2
  givenname: L
  surname: Negrea
  fullname: Negrea, L
– sequence: 3
  givenname: S
  surname: Gunawardhana
  fullname: Gunawardhana, S
– sequence: 4
  givenname: S
  surname: Lopez-Hilker
  fullname: Lopez-Hilker, S
– sequence: 5
  givenname: J
  surname: Finch
  fullname: Finch, J
– sequence: 6
  givenname: T
  surname: Mori
  fullname: Mori, T
– sequence: 7
  givenname: Y
  surname: Nishii
  fullname: Nishii, Y
– sequence: 8
  givenname: E
  surname: Slatopolsky
  fullname: Slatopolsky, E
– sequence: 9
  givenname: A J
  surname: Brown
  fullname: Brown, A J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/2004595$$D View this record in MEDLINE/PubMed
BookMark eNotjz1PwzAURT0UlbYwMyH5Dxj8_J0JoUIBqVIXmCvbeaFBiV3FoRL_ngg6Hd07XJ27JLOUExJyA_wOBPB7THVmIBxTDIyzM7LgHCSzQthLsizla4pKKTknc8G50pVekIddouMBaY_x4FNb-kKbPPxVBTuMY3tC6ifkRHNDT-3o-zbRJ-qT7_JnuSIXje8KXp-5Ih-b5_f1K9vuXt7Wj1sWFVQjg2hQWOknH2Gg0s66wBvngjfKOGMdKB0FWItqUqxjCDF4JTVKh0ZiECty-797_A491vvj0PZ--Nmfj4hfBFlJLg
CitedBy_id crossref_primary_10_1007_s12016_011_8255_1
crossref_primary_10_1177_002215549804601203
crossref_primary_10_1096_fj_01_0584fje
crossref_primary_10_1016_j_parint_2016_11_015
crossref_primary_10_1016_S8756_3282_95_00246_4
crossref_primary_10_1111_j_1774_9987_2004_00191_x
crossref_primary_10_1002_jbmr_5650080815
crossref_primary_10_3390_ijms21093102
crossref_primary_10_1016_S0006_2952_96_00816_7
crossref_primary_10_1002_jcb_240560921
crossref_primary_10_1016_j_bmcl_2010_01_079
crossref_primary_10_1007_s00467_011_2000_0
crossref_primary_10_1038_ki_1993_280
crossref_primary_10_1016_j_ejmech_2020_112738
crossref_primary_10_1016_S1074_5521_99_80072_6
crossref_primary_10_2165_00024677_200201050_00004
crossref_primary_10_1016_S0039_128X_00_00154_9
crossref_primary_10_1016_S0021_9258_20_80689_9
crossref_primary_10_1093_ndt_15_12_1943
crossref_primary_10_1016_S0024_3205_97_01139_9
crossref_primary_10_1210_endo_143_5_8777
crossref_primary_10_1111_1523_1747_ep12371681
crossref_primary_10_1111_j_1939_1676_2006_tb00743_x
crossref_primary_10_1038_ki_1993_83
crossref_primary_10_1111_j_1365_2249_1993_tb08210_x
crossref_primary_10_1007_BF01410133
crossref_primary_10_1016_S0272_6386_97_90571_0
crossref_primary_10_1034_j_1600_0773_2003_920503_x
crossref_primary_10_1046_j_1523_1755_1999_00772_x
crossref_primary_10_1007_BF00762780
crossref_primary_10_1021_bi962080i
crossref_primary_10_1254_fpj_121_65
crossref_primary_10_1046_j_1523_1755_1999_055003821_x
crossref_primary_10_1074_jbc_274_45_32376
crossref_primary_10_1016_S0960_894X_00_80123_7
crossref_primary_10_1016_j_mce_2017_04_008
crossref_primary_10_1007_s002239900175
crossref_primary_10_1016_0145_2126_94_00127_V
crossref_primary_10_1016_0039_128X_94_00072_K
crossref_primary_10_1053_jarr_2002_34845
crossref_primary_10_1016_S0021_9258_18_31690_9
crossref_primary_10_1016_j_jsbmb_2006_12_089
crossref_primary_10_1007_BF01276915
crossref_primary_10_1111_1523_1747_ep12324474
crossref_primary_10_1016_j_ejphar_2016_06_028
crossref_primary_10_1016_S0960_894X_00_80119_5
crossref_primary_10_1038_ncpendmet0394
crossref_primary_10_1016_0098_2997_93_90001_T
crossref_primary_10_1016_0960_0760_95_00089_I
crossref_primary_10_1074_jbc_271_15_8700
crossref_primary_10_1038_ki_1996_283
crossref_primary_10_1152_ajprenal_00336_2004
crossref_primary_10_18632_oncotarget_17968
crossref_primary_10_3389_fmed_2021_790513
crossref_primary_10_1046_j_1523_1755_1999_07305_x
crossref_primary_10_1053_j_semnephrol_2003_08_018
crossref_primary_10_1007_s12018_009_9040_z
crossref_primary_10_1016_0960_0760_95_00218_9
crossref_primary_10_1002_jbmr_5650061207
crossref_primary_10_1152_ajprenal_1999_277_2_F157
crossref_primary_10_1007_BF03194373
crossref_primary_10_1111_j_1440_1797_1998_tb00377_x
crossref_primary_10_1046_j_1523_1755_61_s80_24_x
crossref_primary_10_1007_BF03021403
crossref_primary_10_1016_0006_2952_95_00121_F
crossref_primary_10_1359_jbmr_070202
crossref_primary_10_1016_8756_3282_95_00215_Y
crossref_primary_10_1016_j_semnephrol_2004_06_013
crossref_primary_10_1016_S0039_128X_00_00227_0
crossref_primary_10_1002_jcb_23051
crossref_primary_10_1016_j_steroids_2012_09_008
crossref_primary_10_1210_endo_140_10_7025
crossref_primary_10_1002_jbmr_5650070713
crossref_primary_10_1373_clinchem_2005_059568
crossref_primary_10_1016_j_bmcl_2010_09_011
crossref_primary_10_1136_pgmj_2008_070177
crossref_primary_10_1359_jbmr_1998_13_9_1378
crossref_primary_10_1097_MNH_0000000000000416
crossref_primary_10_1152_physrev_1998_78_4_1193
crossref_primary_10_1021_jo970133b
crossref_primary_10_1046_j_1440_1797_1998_d01_28_x
crossref_primary_10_1111_j_1440_1797_1995_tb00056_x
crossref_primary_10_1208_s12249_018_1231_9
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1210/endo-128-4-1687
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
ExternalDocumentID 2004595
Genre Research Support, U.S. Gov't, P.H.S
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: DK-07126
– fundername: NIDDK NIH HHS
  grantid: DK-09976
GroupedDBID ---
-DZ
-~X
.55
.GJ
.XZ
08P
0R~
18M
1TH
29G
2WC
34G
354
39C
3O-
3V.
4.4
48X
53G
5GY
5RE
5RS
5YH
79B
8F7
AABZA
AACZT
AAIMJ
AAJQQ
AAKAS
AAPGJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAYJJ
ABEFU
ABHFT
ABJNI
ABLJU
ABMNT
ABNHQ
ABPPZ
ABPQP
ABPTD
ABQNK
ABSAR
ABWST
ABXVV
ACFRR
ACGFO
ACGFS
ACIPB
ACIWK
ACPRK
ACUTJ
ACZBC
ADBBV
ADGKP
ADGZP
ADHKW
ADIYS
ADQBN
ADRTK
ADVEK
ADZCM
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFFNX
AFFZL
AFGWE
AFOFC
AFRAH
AFULF
AFXAL
AFYAG
AGINJ
AGKRT
AGMDO
AGQXC
AGUTN
AHMBA
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
APJGH
AQKUS
ARIXL
ATGXG
AVNTJ
BAWUL
BAYMD
BCRHZ
BENPR
BEYMZ
BPHCQ
BSWAC
BTRTY
BVXVI
C1A
C45
CDBKE
CGR
CJ0
CS3
CUY
CVF
DAKXR
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
EMOBN
ENERS
F5P
FA8
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HF~
HZ~
H~9
IAO
IH2
IHR
ITC
J5H
KBUDW
KOP
KQ8
KSI
KSN
L7B
LMP
M5~
MBLQV
MHKGH
MJL
MVM
NLBLG
NOMLY
NOYVH
NPM
NVLIB
O9-
OAUYM
OBH
ODMLO
OFXIZ
OHH
OHT
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
PQQKQ
PROAC
Q-A
REU
ROX
ROZ
TEORI
TJX
TLC
TMA
TR2
TWZ
UPT
VQP
VVN
W2D
W8F
WH7
WHG
WOQ
X52
X7M
XJT
XOL
YBU
YHG
YOC
YQI
YSK
YYP
ZCA
ZCG
ZGI
ZKB
ZXP
ZY1
ID FETCH-LOGICAL-c419t-1c6e273a01326195878b0f88ba6468678145c2177e4144dcbbcba435e38e63eb2
ISSN 0013-7227
IngestDate Sat Sep 28 07:26:48 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c419t-1c6e273a01326195878b0f88ba6468678145c2177e4144dcbbcba435e38e63eb2
PMID 2004595
ParticipantIDs pubmed_primary_2004595
PublicationCentury 1900
PublicationDate 1991-04-01
PublicationDateYYYYMMDD 1991-04-01
PublicationDate_xml – month: 04
  year: 1991
  text: 1991-04-01
  day: 01
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Endocrinology (Philadelphia)
PublicationTitleAlternate Endocrinology
PublicationYear 1991
SSID ssj0014443
Score 1.7632344
Snippet A variety of analogs of 1,25-(OH)2D3 with less calcemic activity and lower receptor binding affinity than 1,25-(OH)2D3 have been developed. However, these...
SourceID pubmed
SourceType Index Database
StartPage 1687
SubjectTerms Animals
Binding, Competitive
Calcitriol - analogs & derivatives
Calcitriol - metabolism
Calcitriol - pharmacokinetics
Calcitriol - pharmacology
Calcium - blood
Dogs
Humans
Macrophages - drug effects
Macrophages - metabolism
Metabolic Clearance Rate
Nephrectomy
Parathyroid Hormone - secretion
Rats
Uremia - etiology
Uremia - metabolism
Vitamin D-Binding Protein - metabolism
Title On the mechanisms for the selective action of vitamin D analogs
URI https://www.ncbi.nlm.nih.gov/pubmed/2004595
Volume 128
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NaxsxEBVNSkIuoc0HafqBDqWXoNLVaiXlVELdYkrjXBLILUhaLTGJtQavD82vz4wk1o6blqSXxUhm2dV7Hs-M3owI-ah04a0tawbOAmdCNppZV1pWVU3DtZVcxAampyM5vBA_L6vLhSAzVpd09rO7e7Su5H9QhTHAFatkn4Fsf1MYgM-AL1wBYbg-CeOzpFGceCzfHc9Sb4U4NIvH26AqKJ8F3uIefGcm43A0ODIBUzazB1n5ULdgQFKWHd1OzLRgC8npNcpp-3TBYA7vlAxK70aOPATtZlHCgHKeeTCox4XnMg8SrL_aqb9jw_HtzfKJX3WuwyuW1CrZlBYlUzwV9vemlOslzoglw1jI9L_6h8WGkDNiV7eswEQfW_0mLPl0EgFE6Kt0JOc_J1caaOeZNbKmNFrCEeZz8j6TEFlXmV8mN3_CuqaVR9oiG_lGKwFIdETOX5HtHEHQk0SH1-SFDztk9ySYrp38pp9o1PRGGHfI5mmWTuySr2eBAjPogiwUyBKHerLQRBbaNjSThQ5oJsseufjx_fzbkOXTM5gTxXHHCic9-KYGN9MkthRS2n5ptLZGCqkltjqrHASkygtYhtpZ66wB59mX2svSW75P1kMb_AGhpeP8mFullJTC41aw8uAZK-l0Y52Xb8h-WpGraWqRcpWX6vBvE2_J1oJU78jLBn6R_j24d539EBG6B5NJSdA
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=On+the+mechanisms+for+the+selective+action+of+vitamin+D+analogs&rft.jtitle=Endocrinology+%28Philadelphia%29&rft.au=Dusso%2C+A+S&rft.au=Negrea%2C+L&rft.au=Gunawardhana%2C+S&rft.au=Lopez-Hilker%2C+S&rft.date=1991-04-01&rft.issn=0013-7227&rft.volume=128&rft.issue=4&rft.spage=1687&rft_id=info:doi/10.1210%2Fendo-128-4-1687&rft_id=info%3Apmid%2F2004595&rft_id=info%3Apmid%2F2004595&rft.externalDocID=2004595
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-7227&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-7227&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-7227&client=summon